Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic imm… Read more
Kaleido Biosciences Inc (KLDO) - Total Assets
Latest total assets as of March 2022: $50.14 Million USD
Based on the latest financial reports, Kaleido Biosciences Inc (KLDO) holds total assets worth $50.14 Million USD as of March 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kaleido Biosciences Inc - Total Assets Trend (2016–2021)
This chart illustrates how Kaleido Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kaleido Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2021)
Kaleido Biosciences Inc's total assets of $50.14 Million consist of 84.4% current assets and 15.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.7% |
| Accounts Receivable | $934.00K | 1.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $5.67 Million | 11.3% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2021)
This chart illustrates how Kaleido Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kaleido Biosciences Inc's current assets represent 84.4% of total assets in 2021, a decrease from 87.4% in 2016.
- Cash Position: Cash and equivalents constituted 76.7% of total assets in 2021, up from 54.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 11.3% of total assets.
Kaleido Biosciences Inc Competitors by Total Assets
Key competitors of Kaleido Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Kaleido Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kaleido Biosciences Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kaleido Biosciences Inc is currently not profitable relative to its asset base.
Kaleido Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.43 | 7.38 | 7.41 |
| Quick Ratio | 1.43 | 7.38 | 7.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.63 Million | $ 82.16 Million | $ 24.70 Million |
Kaleido Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Kaleido Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -15.5% |
| Total Assets | $50.14 Million |
| Market Capitalization | $4.24K USD |
Valuation Analysis
Below Book Valuation: The market values Kaleido Biosciences Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kaleido Biosciences Inc's assets decreased by 15.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kaleido Biosciences Inc (2016–2021)
The table below shows the annual total assets of Kaleido Biosciences Inc from 2016 to 2021.
| Year | Total Assets | Change |
|---|---|---|
| 2021-12-31 | $50.14 Million | -15.51% |
| 2020-12-31 | $59.34 Million | -27.90% |
| 2019-12-31 | $82.31 Million | -3.54% |
| 2018-12-31 | $85.33 Million | +177.51% |
| 2017-12-31 | $30.75 Million | +516.17% |
| 2016-12-31 | $4.99 Million | -- |